Why the study?
Does ivabradine improve safety and maintain efficacy compared to bisoprolol for heart rate reduction before CT coronary angiography in young patients with connective tissue dysplasia?
Cohort (n=65)
No
Does ivabradine improve safety and maintain efficacy compared to bisoprolol for heart rate reduction before CT coronary angiography in young patients with connective tissue dysplasia?
Absolute Event Rate: 8.5% vs 33.3%
p-value: p=0.0363
Ivabradine is as effective as bisoprolol for heart rate reduction before CT coronary angiography in young patients with connective tissue dysplasia, but offers a better safety profile with significantly fewer orthostatic hypotension events.
May support ivabradine preference to reduce orthostatic hypotension pre-CTCA; leaves open need for randomized confirmation in connective tissue dysplasia.
To assess the efficacy and safety application ivabradine to control the heart rate before the procedure computed tomography coronary angiography (CTCA) in young patients with connective tissue dysplasia (CTD) were surveyed 65 patients (age 24,9±6,4 years; 40 men). Patients were divided into 2 groups: group 1 (n=47; 29 men) to achieve the heart rate
No takes yet. Share an insight, caveat, or question.
Друк et al. (2014) conducted a cohort in Connective tissue dysplasia (n=65). Ivabradine vs. Bisoprolol 5-10 mg/day was evaluated on Orthostatic hypotension after CTCA (p=0.0363).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: